Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Heron Therapeutics Sees FY24 Revenue $138M-$158M

Author: Benzinga Newsdesk | March 12, 2024 04:30pm

Financial Guidance for 2024

The Company reaffirms its full-year 2024 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA:

Product Revenues, Net	$138.0 to $158.0 million

Adjusted Operating Expenses (Excluding Stock-Based Compensation and Depreciation and Amortization)	$108.0 to $116.0 million

Adjusted EBITDA (Excluding Stock-Based Compensation and Depreciation and Amortization)	$(22.0) to $3.0 million

Posted In: HRTX